Evotec SE — Regulatory Filings 2016

Mar 10, 2016

News Details

Corporate | 10 March 2016 07:30

Evotec achieves milestone in collaboration with Padlock Therapeutics

DGAP-News: Evotec AG / Key word(s): Miscellaneous

2016-03-10 / 07:30
The issuer is solely responsible for the content of this announcement.

---

Hamburg, Germany - 10 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced the achievement of a key
pre-clinical milestone in the ongoing alliance with its research partner
Padlock Therapeutics, Inc. ("Padlock"). The programme focuses on developing
inhibitors of protein-arginine deiminases ("PADs"), first-in-class
compounds for autoimmune diseases such as rheumatoid arthritis (RA) and
lupus. The milestone triggers a significant milestone payment to Evotec.

The collaboration, now in its third year, could potentially extend through
March 2017. As part of the collaboration, Evotec provides a full range of
research activities and expertise to Padlock including in vitro biology,
high-throughput screening, structural biology, medicinal and computational
chemistry and DMPK. Evotec and Padlock plan to progress multiple programmes
through hit-to-lead and lead optimisation with the goal of achieving
multiple development candidates. Under the terms of the initial agreement,
Evotec was awarded the opportunity to earn success payments and an equity
grant in addition to research payments totaling over $ 13 m.

Dr Michael Gilman, Chief Executive Officer, Padlock Therapeutics,
commented: "We are excited about the swift progress we've made with our
colleagues at Evotec. We have dramatically accelerated our understanding of
the PAD enzyme family and created significant proprietary chemical equity
around PAD inhibitors with the potential to make a meaningful difference in
the lives of people with destructive autoimmune diseases."

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: "We are
delighted about the great achievements in this programme so far and how
Venture Capital-financed virtual start-up companies like Padlock take
advantage of Evotec's technological platform. We believe the combination of
partnerships with asset-centric start-up companies and our industrial
infrastructure creates tremendous value and will ensure that the
therapeutic programmes advance with increasing capital efficiency to
discover molecules for clinical testing."

ABOUT PADLOCK THERAPEUTICS, INC.
Padlock Therapeutics is a private, Cambridge, Massachusetts-based
biotechnology company dedicated to creating new medicines to treat
destructive autoimmune diseases. The company leverages the breakthrough
science on the role of protein citrullination in disease to develop drugs
targeting protein-arginine deiminase (PAD) enzymes. Padlock was founded by
scientists at The Scripps Research Institute in conjunction with Atlas
Venture. Padlock's Series A investors include Atlas Ventures, Johnson &
Johnson Innovation - JJDC, MS Ventures, and Index Ventures. For more
information on Padlock, visit www.padlocktherapeutics.com.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

---

2016-03-10 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart; Terminbörse EUREX

 End of News    DGAP News Service